Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$19.09 USD
+0.48 (2.58%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $19.19 +0.10 (0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Summit Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 2 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 2 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 610 | 73 | 88 | 54 | 28 |
Income After Depreciation & Amortization | -610 | -72 | -86 | -53 | -27 |
Non-Operating Income | -5 | -7 | -2 | 0 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -615 | -79 | -89 | -53 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -615 | -79 | -89 | -53 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -615 | -79 | -89 | -53 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -608 | -70 | -84 | -51 | -26 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -610 | -72 | -86 | -53 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 621.11 | 192.15 | 92.29 | 69.34 | NA |
Diluted EPS Before Non-Recurring Items | -0.15 | -0.41 | -0.96 | -0.75 | NA |
Diluted Net EPS (GAAP) | -0.99 | -0.41 | -0.96 | -0.76 | NA |
Fiscal Year end for Summit Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 59.62 | 42.39 | 36.21 | 20.49 | 15.79 |
Income After SG&A, R&D, and Dept/Amort Expenses | -59.62 | -42.39 | -36.21 | -20.49 | -15.79 |
Non-Operating Income | -0.77 | -1.08 | -0.36 | -0.78 | 1.08 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -60.39 | -43.47 | -36.57 | -21.27 | -14.72 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -60.39 | -43.47 | -36.57 | -21.27 | -14.72 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -60.39 | -43.47 | -36.57 | -21.27 | -14.72 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 671.11 | 725.00 | 732.00 | 708.93 | 735.85 |
Diluted EPS Before Non-Recurring Items | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 |
Diluted Net EPS (GAAP) | -0.09 | -0.06 | 0.49 | -0.03 | -0.02 |